CPA
TEVA icon

Cowen Prime Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Cowen Prime Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$475K Buy
63,040
+1,000
+2% +$8.11K 0.16% 61
2023
Q1 		$542K Sell
62,040
-3,000
-5% -$29.7K 0.22% 57
2022
Q4 		$593K Buy
65,040
+24,300
+60% +$212K 0.24% 56
2022
Q3 		$329K Hold
40,740
– – 0.19% 55
2022
Q2 		$306K Buy
40,740
+10,000
+33% +$87.1K 0.17% 60
2022
Q1 		$289K Sell
30,740
-300
-1% -$2.5K 0.12% 74
2021
Q4 		$249K Sell
31,040
-50,254
-62% -$454K 0.08% 76
2021
Q3 		$792K Hold
81,294
– – 0.29% 56
2021
Q2 		$805K Hold
81,294
– – 0.29% 52
2021
Q1 		$938K Hold
81,294
– – 0.35% 52
2020
Q4 		$784K Hold
81,294
– – 0.35% 46
2020
Q3 		$732K Buy
81,294
+40,554
+100% +$429K 0.36% 46
2020
Q2 		$306K Sell
40,740
-40,554
-50% -$459K 0.17% 60
2020
Q1 		$730K Hold
81,294
– – 0.45% 43
2019
Q4 		$797K Sell
81,294
-860
-1% -$7.68K 0.36% 43
2019
Q3 		$565K Hold
82,154
– – 0.29% 51
2019
Q2 		$758K Hold
82,154
– – 0.37% 48
2019
Q1 		$1.29M Sell
82,154
-1,750
-2% -$30.9K 0.67% 40
2018
Q4 		$1.29M Buy
83,904
+17,350
+26% +$356K 0.78% 37
2018
Q3 		$1.43M Sell
66,554
-550
-0.8% -$12.8K 0.67% 46
2018
Q2 		$1.63M Sell
67,104
-3,335
-5% -$68K 0.8% 35
2018
Q1 		$1.2M Sell
70,439
-700
-1% -$13.7K 0.67% 45
2017
Q4 		$1.35M Sell
71,139
-74,700
-51% -$1.12M 0.66% 45
2017
Q3 		$2.57M Sell
145,839
-3,600
-2% -$81K 1.22% 26
2017
Q2 		$4.96M Buy
149,439
+300
+0.2% +$9.29K 2.29% 14
2017
Q1 		$4.79M Buy
149,139
+7,900
+6% +$270K 2.46% 13
2016
Q4 		$5.12M Buy
141,239
+700
+0.5% +$27.9K 2.76% 11
2016
Q3 		$6.47M Buy
140,539
+3,200
+2% +$167K 2.94% 6
2016
Q2 		$6.9M Sell
137,339
-200
-0.1% -$10.6K 3.35% 6
2016
Q1 		$7.36M Buy
137,539
+400
+0.3% +$23.5K 3.41% 8
2015
Q4 		$9M Hold
137,139
– – 3.97% 7
2015
Q3 		$7.74M Sell
137,139
-1,590
-1% -$103K 3.61% 6
2015
Q2 		$8.2M Sell
138,729
-1,756
-1% -$108K 3.21% 6
2015
Q1 		$8.75M Sell
140,485
-691
-0.5% -$40.2K 3.6% 7
2014
Q4 		$8.12M Buy
141,176
+2,807
+2% +$156K 3.2% 8
2014
Q3 		$7.44M Buy
138,369
+10
+0% +$530 3.25% 8
2014
Q2 		$7.25M Sell
138,359
-290
-0.2% -$14.8K 2.85% 8
2014
Q1 		$7.33M Buy
138,649
+35,385
+34% +$1.64M 2.77% 10
2013
Q4 		$4.14M Buy
103,264
+1,414
+1% +$55.7K 1.59% 18
2013
Q3 		$3.85M Buy
101,850
+2,117
+2% +$82.6K 1.5% 16
2013
Q2 		$3.89M Buy
+99,733
New +$3.88M 1.62% 13

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cowen Prime Advisors's TEVA Position: Q2 2023 in Review

Cowen Prime Advisors increased its Teva Pharmaceuticals (TEVA) stake by 1.6% in Q2 2023, buying an estimated $8.11K and bringing the position to 63,040 shares worth $475K. The position accounts for 0.16% of the portfolio, ranked #61.

Cowen Prime Advisors first reported a position in TEVA in Q2 2013 and has held it in 41 quarters since. The position peaked at $9M in Q4 2015. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Cowen Prime Advisors held 63,040 shares of Teva Pharmaceuticals worth $475K as of Q2 2023.
  • Cowen Prime Advisors bought 1,000 Teva Pharmaceuticals shares in Q2 2023, an estimated $8.11K.
  • Teva Pharmaceuticals made up 0.16% of Cowen Prime Advisors's portfolio in Q2 2023, its #61 holding.
  • Cowen Prime Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • Cowen Prime Advisors's Teva Pharmaceuticals position peaked at $9M in Q4 2015.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Cowen Prime Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.